Clinical Trials at Carolinas Medical Center/Levine Cancer Institute

As of July 2026, 57 paid clinical trials are recruiting at Carolinas Medical Center/Levine Cancer Institute, located at Atrium Health Levine Cancer Institute, 1021 Morehead Medical Dr, Charlotte, NC 28204, phone (980) 442-2000 in Charlotte, North Carolina. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

57 clinical trials at Carolinas Medical Center/Levine Cancer Institute

·Clear filters·↓ Download CSV

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

for Central Nervous System Nongerminomatous Germ Cell Tumor

149 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 3 - 29

Code: NCT04684368·Phase 2·Recruiting

Apply to this trial

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

for Stage I Mixed Cell Type Kidney Wilms Tumor

146 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 30

Code: NCT06401330·Phase 3·Recruiting

Apply to this trial

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

for Down Syndrome

Drug: Nivolumab

209 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 1 - 30

Code: NCT04546399·Phase 2·Recruiting

Apply to this trial

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

for Embryonal Rhabdomyosarcoma

165 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT05304585·Phase 3·Recruiting

Apply to this trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

152 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting

Apply to this trial

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

for Acute Leukemia of Ambiguous Lineage

Drug: Venetoclax

112 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 365 Days

Code: NCT06317662·Phase 2·Recruiting

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

156 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting

Apply to this trial

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

for Low Grade Astrocytoma

Drug: Selumetinib

124 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 2 - 21

Code: NCT04166409·Phase 3·Recruiting

Apply to this trial

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

for Childhood Medulloblastoma

101 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 4 - 21

Code: NCT05382338·Phase 3·Recruiting

Apply to this trial

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

for Stage II Nasopharyngeal Carcinoma AJCC v8

Drug: Nivolumab

76 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 21

Code: NCT06064097·Phase 2·Recruiting

Apply to this trial

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

for Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

17 locations incl. Tampa

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05172245·Phase 1·Recruiting

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

for Astrocytoma, IDH-Mutant, Grade 2

43 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06860594·Phase 1·Recruiting

Apply to this trial

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

for Extensive Stage Lung Small Cell Carcinoma

Drug: Atezolizumab

43 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06287775·Phase 1, Phase 2·Recruiting

Apply to this trial

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

for Acute Myeloid Leukemia

22 locations incl. Orange

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 75

Code: NCT05886049·Phase 1·Recruiting

Apply to this trial

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

for Glioblastoma, IDH-Wildtype

12 locations incl. Los Angeles

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT06319027·Phase 2·Recruiting

Apply to this trial

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy

for Estrogen Receptor Negative

8 locations incl. Gilbert

Sponsor: M.D. Anderson Cancer Center

Sex: Female·Age: 30+

Code: NCT02945579·Recruiting

Apply to this trial

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

for Mantle Cell Lymphoma

7 locations incl. New Orleans

Sponsor: Academic and Community Cancer Research United

Sex: All·Age: 18 - 75

Code: NCT04626791·Phase 2·Recruiting

Apply to this trial